HALO vs. RVTY: Halozyme Therapeutics vs. Revvity Stock Comparison

November 11, 2026

How do Halozyme Therapeutics (HALO) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Halozyme Therapeutics (HALO) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Profile Item	HALO	RVTY
Name	Halozyme Therapeutics Inc.	Revvity Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	11.81 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	March 16, 2004	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

HALO

RVTY

GSPC

Halozyme Therapeutics (HALO) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Halozyme Therapeutics (HALO) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Halozyme Therapeutics (HALO) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
Total Return (1Y)	50.94%	76.75%
Total Return (3Y, Annualized)	41.08%	24.22%
Total Return (5Y, Annualized)	21.68%	-1.48%

Risk Profile

Drawdown History

HALO

RVTY

GSPC

Halozyme Therapeutics (HALO) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Halozyme Therapeutics (HALO) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
Volatility (1Y, Annualized)	41.19%	40.22%
Beta (5Y)	0.96	1.07
Max Drawdown (5Y)	-49.06%	-59.01%
Avg. Volume (3M)	2.29M	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

HALO and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
Sharpe Ratio (1Y)	1.13	1.80
Sortino Ratio (1Y)	1.78	2.90

Profitability

ROE (TTM)

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Revvity (RVTY) at 3.45%, which is closer to a typical peer reading.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Halozyme Therapeutics (HALO) at 59.84% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
ROE (TTM)	216.38%	3.45%
ROA (TTM)	22.42%	2.54%
Net Margin (TTM)	26.93%	8.61%
Operating Margin (TTM)	59.84%	17.06%
Gross Margin (TTM)	77.74%	55.91%

Growth

Revenue Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Halozyme Therapeutics (HALO) at -25.36% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
Revenue Growth (YoY)	37.55%	3.67%
Revenue Growth (3Y CAGR)	28.38%	-4.82%
EPS Growth (YoY)	-25.36%	-5.91%
EPS Growth (3Y CAGR)	21.14%	-23.26%

Financial Strength

Current Ratio (MRQ)

Both Halozyme Therapeutics (HALO) at 3.88 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Revvity (RVTY) carries debt-to-equity ratio of 0.38 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): HALO does not report debt-to-equity ratio, so it has no value marker; RVTY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
Current Ratio (MRQ)	3.88	2.65
Debt / Equity (MRQ)	--	0.38
Net Debt / EBITDA	1.90	2.43

Dividends

Dividend Yield (TTM)

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
Dividend Yield (TTM)	0.00%	0.19%
Dividend Payout Ratio (TTM)	0.00%	13.40%

Valuation

P/E Ratio (TTM)

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Revvity (RVTY) reports 2.39, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Halozyme Therapeutics (HALO) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Halozyme Therapeutics (HALO) and Revvity (RVTY)
Metric	HALO	RVTY
P/E Ratio (TTM)	25.91	68.94
P/S Ratio (TTM)	6.55	5.88
P/B Ratio (MRQ)	-213.67	2.39
Free Cash Flow Yield (TTM)	3.48%	3.62%